Harmony Biosciences' Releases Topline Results From INTUNE Phase 3 Study Of Pitolisant For Idiopathic Hypersomnia; No Statistically Significant Difference Was Observed Between Pitolisant And Placebo Groups On Epworth Sleepiness Scale, The Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences has released topline results from the INTUNE Phase 3 study of pitolisant for idiopathic hypersomnia. The study found no statistically significant difference between pitolisant and placebo groups on the Epworth Sleepiness Scale, which was the primary endpoint.
October 13, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The lack of significant results from Harmony Biosciences' Phase 3 study of pitolisant may negatively impact the company's stock price in the short term.
The Phase 3 study results are critical for the approval and commercialization of a drug. The lack of significant results may lead to skepticism about the drug's efficacy, potentially impacting the company's stock negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100